Pharmacotherapy of the third-generation AEDs: Lacosamide, retigabine and eslicarbazepine acetate

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 5, 2012, Pages 699-715

  Patsalos, Philip N ^a,b   Berry, David J ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EPILEPSY SOCIETY   (United Kingdom)

^c NONE

Author keywords

Adverse effect profiles; Drugdrug interactions; Efficacy profiles; Eslicarbazepine acetate; Lacosamide; Novel mechanisms of action; Pharmacokinetics; Retigabine; Therapeutic drug monitoring; Third generation antiepileptic drugs

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIGOXIN; ESLICARBAZEPINE ACETATE; ETHINYLESTRADIOL; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; METFORMIN; OMEPRAZOLE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; PRIMIDONE; RETIGABINE; STEDESA; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADJUVANT THERAPY; AMNESIA; ANXIETY; APHASIA; ASTHENIA; ATAXIA; ATTENTION DEFICIT DISORDER; BALANCE DISORDER; BLURRED VISION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; COORDINATION DISORDER; DEPRESSION; DIABETIC NEUROPATHY; DIARRHEA; DIPLOPIA; DISORIENTATION; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; DYSURIA; EUPHORIA; FATIGUE; FIBROMYALGIA; FLATULENCE; FOCAL EPILEPSY; GAIT DISORDER; HALLUCINATION; HEADACHE; HEMATURIA; HUMAN; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MAINTENANCE DRUG DOSE; MALAISE; MEMORY DISORDER; MIGRAINE; MYOCLONUS; NAUSEA; NEUROPATHIC PAIN; NYSTAGMUS; PARESTHESIA; PERIPHERAL EDEMA; PRURITUS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; TREMOR; URINARY HESITANCY; VERTIGO; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ACETAMIDES; ANTICONVULSANTS; CARBAMATES; DIBENZAZEPINES; DRUG INTERACTIONS; EPILEPSY; HUMANS; PHENYLENEDIAMINES;

EID: 84858641737     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.667803     Document Type: Review

References (129)

1. Tomson T, Beghi E, Sundqvist A, Johannessen SI. Medical risks in epilepsy: A review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Res 2004;60:1-16 (Pubitemid 38981756)
2. Perucca E. Pharmacoresistance in epilepsy. How should it be defined? CNS Drugs 1998;10:171-9 (Pubitemid 28449011)
3. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011;10:446-56
4. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-19 (Pubitemid 30075244)
5. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: Effect of past treatment history. Neurology 2008;70:54-65
6. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-77
7. Berg AT, Levy SR, Testa FM, et al. Remission of epilepsy after two drug failures in children: A prospective study. Ann Neurol 2009;65:510-19
8. Callaghan B, Schlesinger M, Rodemer W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 2011;52:619-26
9. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: General features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347-56 (Pubitemid 38352562)
10. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81 (Pubitemid 36876104)
11. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010;10(1):119-40
12. Chung SS. New treatment option for partial-onset seizures: Efficacy and safety of lacosamide. Ther Adv Neurol Disord 2010;3:77-83
13. Vimpat, SPC, UCB Pharma, Slough, Berkshire, UK. Available from: http:// www.medicines.org.uk/emc/medicines/ 21158
14. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1-43
15. Stohr T, Kupferberg HJ, Stables JP, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007;74:147-54 (Pubitemid 46654745)
16. Errington AC, Stohr T, Heers C, et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008;73:157-69 (Pubitemid 350294207)
17. Curia G, Biagini G, Perucca E, et al. Lacosamide: A new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009;23:555-68
18. Kropeit D, Schiltmeyer B, Cawello W, et al. Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia 2004;45(Suppl 7):123-4
19. Rosenfeld W, Biton V, Mameniskiene R, et al. Pharmacokinetics and safety of lacosamide administered as a replacement for adjunctive oral Lacosamide in patients with partial onset seizures. Epilepsia 2005;46(Suppl 8):184
20. Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide in patients with partial onset seizures. Epilepsia 2008;49:418-24
21. Cawello W, Kropeit D, Schiltmeyer B, et al. Food does not affect the pharmacokinetics of SPM 927. Epilepsia 2004;45(Suppl 7):307
22. Doty P, Rudd GD, Stohr T, et al. Lacosamide. Neurotherapeutics 2007;4:145-8 (Pubitemid 46107317)
23. Sattler A, Schaefer M, May TW, et al. Fluctuation of Lacosamide serum concentrations during the day and occurrence of adverse drug reactions - first clinical experience. Epilepsy Res 2011;95(3):207-12
24. Horstmann R, Bonn R, Cawello W, et al. Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927. Epilepsia 2002;43(Suppl 7):188
25. Kelemen A, Halasz P. Lacosamide for the prevention of partial onset seizures in epileptic adults. Neuropsychol Dis Treat 2010;6:465-71
26. Greenaway C, Ratnaraj N, Sander JW, Patsalos PN. Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia 2011;52:258-63
27. Schiltmeyer B, Cawello W, Kropeit D, et al. Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender. Epilepsia 2004;45(Suppl 7):313
28. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: A review of preclinical properties. CNS Drug Rev 2007;13:21-42 (Pubitemid 46697839)
29. Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol 2010;50:459-71
30. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50(3):443-53
31. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-17 (Pubitemid 47063096)
32. Jatuzis D, Biton V, Ben-Menachem E, et al. Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures. Epilepsia 2005;46(Suppl 8):170
33. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia 2010;51:958-67
34. Chung S, Ben-Menachem E, Sperling MR, et al. Examining the clinical utility of lacosamide: Pooled analyses of three phase 2/3 clinical trials. CNS Drugs 2010;24:1041-54
35. Sake JK, Hebert D, Isojarvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010;24:1955-68
36. Novy J, Patsalos PN, Sander JW, et al. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: A pharmacodynamic interaction? Epilepsy Behav 2011;20:20-23
37. Cuzzola A, Ferlazzo E, Italiano D, et al. Does lacosamide aggravate Lennox-Gastaut syndrome? Report on three consecutive cases. Epilepsy Behav 2010;19:650-1
38. Gavatha M, Ioannou I, Papavasiliou AS. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav 2011;20:691-3
39. Guilhoto LM, Loddenkemper T, Gooty VD, et al. Experience with lacosamide in a series of children with drug resistant focal seizures. Pediatr Neurol 2011;44:414-19
40. Kellinghaus C, Berning S, Immisch I, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand 2011;123:137-41
41. Albers JM, Moddel G, Dittrich R, et al. Intravenous lacosamide-an effective add-on treatment of refractory status epilepticus. Seizure 2011;21:428-30
42. Rantsch K, Walter U, Wittsrock M, et al. Efficacy of intravenous lacosamide in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Seizure 2011;20(7):529-32
43. Shiloh-Malawsky Y, Fan Z, Greenwood R, et al. Successful treatment of childhood prolonged status epilepticus with lacosamide. Seizure 2011;20(7):586-8
44. Koubeissi MZ, Mayor CL, Estephan B, et al. Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus. Acta Neurol Scand 2011;123:142-6
45. Chen LL, Haneef Z, Dorsch A, et al. Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam. Seizure 2011;20:263-5
46. Parkerson KA, Reinsberger C, Chou SH, et al. Lacosamide in the treatment of acute recurrent seizures and periodic epileptiform patterns in critically ill patients. Epilepsy Behav 2011;20:48-51
47. Goodwin H, Hinson HE, Shermock KM, et al. The use of lacosamide in refractory status epilepticus. Neurocrit Care 2011;14:348-53
48. Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav 2011;20:725-7
49. Krauss G, Ben-Menachem E, Mameniskiene R, et al. Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia 2010;51:951-7
50. Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav 2010;18:322-4
51. Prunetti P, Perucca E. New and forthcoming antiepileptic drugs. Curr Opin Neurol 2011;24:159-64
52. Vimpat PI. Summary of Product Characteristics, Lacosamide, Vimpat, UCB Pharma Ltd, Bath, UK 2011
53. Bauer S, Rudd D, Mylius V, et al. Lacosamide intoxication in attempted suicide. Epilepsy Behav 2010;17:549-51
54. McMullin M, Dalrymple R. Analysis for lacosamide in human serum by LC/MS/ MS and a summary of 8,000 patient values. Ther Drug Monit 2011;33(4):520-1
55. Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-76 (Pubitemid 351991390)
56. Czuczwar P, Wojtak A, Cioczek-Czuczwar A, et al. Retigabine: The newer potential antiepileptic drug. Pharmacol Rep 2010;62(2):211-19
57. Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics 2007;4:149-54
58. Tober C, Rundfeldt C, Rostock A, et al. The phenyl carbamic acid ester D-23129 is highly effective in epilepsy models for generalized and focal seizures at nontoxic doses. Abstr Soc Neurosci 1994;20:1641
59. Dailey JW, Cheong JH, Kh K, et al. Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: Prediction of clinical response. Neurosci Lett 1995;195:77-80
60. Kapetanovic IM, Rundfeldt C. D23129: A new anticonvulsant compound. CNS Drugs Rev 1996;2:308-21
61. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 2000;282:73-6 (Pubitemid 30129172)
62. Rostock A, Tober C, Rundfeldt C, et al. D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-23 (Pubitemid 26176549)
63. Main MJ, Cryan JE, Dupere JR., et al. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000;58:253-62 (Pubitemid 30497468)
64. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92:89-124
65. Main MJ, Cryan JE, Dupere JR, et al. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000;58:253-62 (Pubitemid 30497468)
66. Wuttke TV, Seebohm G, Bail S, et al. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-17 (Pubitemid 40410403)
67. + channels. Mol Pharmacol 2009;75:272-80
68. Wickenden AD, Yu W, Zou A, et al. Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000;58:591-600
69. Tatulian L, Brown DA. Effects of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J Physiol 2003;549(Pt 1):57-63 (Pubitemid 36626397)
70. Ferron GM, Paul J, Fruncillo R, et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002;42:175-82 (Pubitemid 34101350)
71. Hermann R, Ferron GM, Erb K, et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003;73:61-70 (Pubitemid 36158487)
72. Summary of Product Characteristics, Eslicarbazepine acetate, Zebinix, EISAI. Hatfield, Hertfordshire, UK 2011
73. Hemple R, Schupke H, McNeilly PJ, et al. Metabolism of retigabine (D- 23129), a novel anticonvulsant. Drug Metab Dispos 1999;27:613-22 (Pubitemid 29214474)
74. McNeilly PJ, Torchin CD, Anderson LW, et al. In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 1997;27:431-41 (Pubitemid 27220177)
75. Hiller A, Nguyen N, Strassburg CP, et al. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 1999;27:605-12 (Pubitemid 29214473)
76. Hermann R, Borlak J, Munzel U, et al. The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine. Pharmacogenomics J 2006;6:211-19 (Pubitemid 43811572)
77. Mansbach H, Baulac M. Retigabine. In: Shorvon S, Perucca E, Engle J, editors. The Treatment of Epilepsy. 3rd edition. Blackwell Publishing; Chichester: 2009. p. 637-46
78. Ferron GM, Patat A, Parks V, et al. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol 2003;56:39-45 (Pubitemid 36886487)
79. Ferron GM, Sachdeo R, Pardot A, et al. Pharmacokinetic interaction between valproic acid, topiramate, phenytoin or carbamazepine and retigabine in epileptic patients. Clin Pharm Ther 2001;69:18
80. Paul J, Ferron GM, Richards L, et al. Retigabine does not alter the pharmacokinetics of a low-dose oral contraceptive in women. Neurology 2001;56(Suppl 3):A335-6
81. Porter RJ, Partiot A, Sachdeo R, et al. Randomised multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007;68:1197-204 (Pubitemid 46608467)
82. Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-24
83. French JA, Abou-Khalil BW, Leroy RF, et al. Randomised, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555-63
84. + channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 2004;172(5 Pt):2054-8 (Pubitemid 39363127)
85. Rode F, Svalo J, Sheykhzade M, et al. Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder. Eur J Pharmacol 2010;638:121-7
86. Rauchenzauner M, Luef G. Update on treatment of partial onset epilepsy: Role of eslicarbazepine. Neuropsychiatry Dis Treat 2010;6:723-30
87. Brown ME, El-Mallakh RS. Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures. Ther Clin Risk Manag 2010;6:103-9
88. McCormack PL, Robinson DM. Eslicarbazepine acetate. CNS Drugs 2009;23:71-9
89. Ambrosio AF, Soares-da-Silva P, Carvalho CM, et al. Mechanism of action of carbamazepine. Oxcarbazepine, BIA-2-093, and BIA-2-024. Neurochem Res 2002;27:121-30
90. Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro- 5H-dibenz[b,f]azepine- 5-carboxamide derivatives. J Med Chem 1999;42:2582-7 (Pubitemid 29344298)
91. Ambrosio AF, Silva AP, Araujo I, et al. Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur J Pharmacol 2000;46:191-201
92. Ambrosio AF, Silva AP, Malva JO, et al. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol 2001;61:1271-5 (Pubitemid 32375119)
93. Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007;4:88-96 (Pubitemid 46107316)
94. Parada A, Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: A comparison with carbamazepine and oxcarbazepine. Neurochem Int 2002;40:435-40 (Pubitemid 34121989)
95. Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetics profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs 2003;4:269-84 (Pubitemid 37184388)
96. Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetics profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 2004;44:906-18 (Pubitemid 38971573)
97. Almeida L, Falcao A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005; 45:1062-6 (Pubitemid 41192366)
98. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004;61:1-48 (Pubitemid 39296697)
99. Maia J, Vaz-da-Silva M, Almeida L, et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D 2005;6:201-6 (Pubitemid 40994241)
100. Fontes-Ribeiro C, Macedo T, Nunes T, et al. Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: Randomized, ope-label, crossover, single-centre study in healthy volunteers. Drugs R D 2008;9:447-54
101. Fontes-Ribeiro C, Macedo T, Falcao A, et al. Eslicarbazepine acetate (BIA 2- 093): Relative bioavailability and bioequivalence of 50 mg/ml oral suspension and 200 mg and 800 mg tablet formulations. Drugs R D 2005;6:253-60
102. Loureiro AI, Fernandes-Lopes C, Bonifacio MJ, et al. Hepatic UDP-glucuronosyltransferase responsible for esclicarbazepine glucuronidation. Drug Metab Dispos 2011; [Epub ahead of print]
103. Perucca E, Elger C, Halasz P, et al. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res 2011;96:132-9
104. Falcao A, Maia J, Almeida L, et al. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 2007;28:249-56 (Pubitemid 47180174)
105. Van Heininggen PNM, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50:410-19
106. Battino D, Estienne M, AVanzini G. Clinical pharmacokinetics of antiepileptic drugs in pediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 1995; 29:341-69
107. Maia J, Almeida L, Falcao A, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 2008;46:119-30 (Pubitemid 351721154)
108. Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994; 47:161-7 (Pubitemid 24314737)
109. Almeida L, Potgieter JH, Maia J, et al. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008; 64:267-73
110. Fortuna A, Alves G, Falcao A, et al. Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharm Drug Dispos 2010; 31:362-6
111. Patsalos PN, Elyas AA, Zakrewska JM. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbamazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol 1990; 39:413-15 (Pubitemid 20362358)
112. Zhang C, Zuo Z, Kwan P, et al. In vitro transport profile of carbamazepine, oxcarbazepine, Eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 2011;52(10):1894-904
113. Fuseau E, Fabre MA, Falcao A, et al. Population pharmacokinetics of eslicarbazepine acetate in adult patients with refractory partial seizures. Epilepsia 2008;49:432
114. Zebin Dex SPC 2011
115. Almeida L, Nunes T, Sicard E, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand 2010; 121:257-64
116. Nunes T, Sicard E, Almeida L, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin 2010; 26:1355-62
117. Rocha JF, Vaz-da-Silva M, Almeida L, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther 2009;47:255-61
118. Vaz-da-Silva M, Costa R, Soares E, et al.Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol 2009;23:509-14
119. Vaz-da-Silva M, Almeida L, Falcao A, et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage open-label, multiple-dose, single-period study. Clin Ther 2010;32:179-92
120. Elger C, Halasz P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454-63
121. Gil-Nagel A, Lopes-Lima J, Almeida L, et al. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009;120:281-7
122. Ben-Menachem E, Gabbai AA, Huffnagel A, et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res 2010;89:278-85
123. Elger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007;48:497-504 (Pubitemid 46365199)
124. Almeida L, Minciu I, Nunes T, et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol 2008;48:966-77 (Pubitemid 352009492)
125. Vaz-da-Silva M, Nunes T, Almeida L, et al. Evaluation of eslicarbazepine acetate on cardiac repolarisation in a thorough QT/QTc study. J Clin Pharmacol 2011; [Epub ahead of print]
126. Physicians' Desk Reference. 5th edition. Medical Economics Co.; Montvale, NJ: 2001
127. Miles MV, Tang PH, Ryan MA, et al. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). Ther Drug Monit 2004;26(3):300-4 (Pubitemid 38703018)
128. Patsalos PN, Bourgeois BFD. The Epilepsy Prescriber's Guide to Antiepileptic Drugs. Cambridge University Press; Cambridge: 2010
129. Fattore C, Perucca E. Novel medications for epilepsy. Drugs 2011;71:2151-78